Women with Alzheimer's disease show faster cognitive decline compared to men, even though they have similar levels of pathological markers of the disease[1]. Research based on multi-cohort analysis has shown that when amyloid-beta is present, women have higher baseline levels of phosphorylated tau 217 (p-tau217), an important biomarker of Alzheimer's disease[1]. These findings suggest that women may be more prone to develop symptoms of the disease more rapidly despite having similar biological characteristics to men[1]. Alzheimer's disease is a chronic progressive disease of the nervous system caused by the degenerative death of neurons[1]. The difference in the course of the disease between the sexes may have implications for the diagnosis and treatment of patients[1]. These findings point to the need to take into account the patient's gender in the assessment and treatment of Alzheimer's disease[1].